

Glycerol Effective for Children's Bacterial Meningitis

BY MITCHEL L. ZOLER
Philadelphia Bureau

WASHINGTON — Adjunctive treatment with oral glycerol was more effective than intravenous dexamethasone for preventing death and severe neurologic sequelae in children with bacterial meningitis in a controlled study with 640 patients.

"Because oral glycerol is safe, cheap, and easily available and does not have special storage requirements, it seems to be the

best approach for improving the outcome of bacterial meningitis in children," Heikki Peltola, M.D., said at the annual Interscience Conference on Antimicrobial Agents and Chemotherapy.

Although dexamethasone is often used as an adjunctive treatment for children with bacterial meningitis, its efficacy has never been proven. Several physicians have hypothesized that glycerol would be an effective adjunctive agent because of its activity as a free-radical scavenger.

To test both agents, a study was done in the pediatric departments of 10 university hospitals in South America and Helsinki, Finland.

The study was supported by a grant from GlaxoSmithKline, but the study's design, conduct, and analysis were independent of commercial influence, said Dr. Peltola, a professor of infectious diseases at the Hospital for Children and Adolescents at Helsinki University Central Hospital.

Children aged 2 months or older with bacterial meningitis were all treated with ceftriaxone. They were also randomized to one of four adjunctive treatment groups: dexamethasone only, glycerol only, both dexamethasone and glycerol, or placebo. About 160 patients were randomized to each treatment group.

Patients treated with glycerol received a dosage of 6.0 g/kg daily, given orally in four divided doses. Patients who received dexamethasone were given a dosage of

Most Don't Present With Meningitis Triad

WASHINGTON — Less than half of patients with bacterial meningitis have the classic symptom triad of fever, stiff neck, and a change in mental status, Diederick van de Beek, M.D., said while presenting a poster at the annual Interscience Conference on Antimicrobial Agents and Chemotherapy.

Many patients present with just two classic symptoms, one of which may also be headache, said Dr. van de Beek, a neurologist at the Academic Medical Center in Amsterdam.

In a review of 696 patients with community-acquired, acute bacterial meningitis, the classic symptom triad occurred in only 44% of the patients, Dr. van de Beek reported in his poster. (The data have been published: *N. Engl. J. Med.* 2004;351:1849-59).

In contrast, 95% of patients had at least two classic symptoms. The most common classic symptom was headache in 87%, followed by neck stiffness in 83%, fever in 77%, and a change in mental status in 69% (defined as a Glasgow Coma Scale score of less than 14).

Of the 696 patients, 21% died and 13% had other unfavorable outcomes including a vegetative state or severe or moderate disability. The likelihood that a patient would have an unfavorable outcome was sixfold higher among patients who were infected with *Streptococcus pneumoniae* than among those infected with *Neisseria meningitidis* when the incidence rates were adjusted for potential clinical confounders.

This study is the first report of a prospective, large-scale analysis of the clinical factors associated with bacterial meningitis and its outcomes, Dr. van de Beek said at the conference, sponsored by the American Society for Microbiology. The study data were drawn from information on all patients who were at least 16 years old and diagnosed with bacterial meningitis in the Netherlands Reference Laboratory database from October 1998 through April 2002.

Of 1,108 cases in the database, complete data were retrieved for 754 patients, of whom 58 were excluded either because their infection was nosocomial, they had had recent neurosurgery, or they had received a neurosurgical device.

—Mitchel L. Zoler


Rethinking Influenza Vaccination

Helping to Stimulate the Natural Defense Pathways

Patients count on an effective vaccine

Many people have come to rely on influenza vaccines—parents of young children, people at high risk for influenza-related complications, healthcare workers, and healthy people who simply want to avoid getting the flu.

Influenza vaccines are prepared in advance of the season and comprise the 3 strains predicted by the US Public Health Service and the World Health Organization to be most prevalent in the coming season. The vaccine is available as either a nasally administered, attenuated, live cold-adapted influenza vaccine (CAIV), or as injectable trivalent influenza vaccines that contain inactivated virus.



0.6 mg/kg daily, administered intravenously in four divided doses. All adjunctive treatments were administered for 2 days, and the children were followed until the end of their hospitalization. The primary end points of the study were death and severe neurologic sequelae, including blindness, profound hearing loss, quadriplegia or paraplegia, hydrocephalus requiring placement of a shunt, and/or severe psychomotor retardation.

Patients treated with glycerol had a 42% reduced risk of death, compared with placebo, a statistically significant difference. Patients treated with dexametha-

none had a 15% reduced risk of death, compared with placebo, a difference that was not statistically significant. Patients who received both treatments had a mortality reduction of 32%.

In all groups, the benefit of adjunctive treatment was best in the subgroup of patients with the most severe disease at baseline, those with a Glasgow Coma Scale score of less than 13. In this subgroup, mortality was

cut by 21% among patients treated with dexamethasone, and by 61% among those treated with glycerol, said Dr. Peltola at

'The mechanisms of glycerol's effect are not fully understood, but improved cerebral circulation seems a likely explanation.'

the conference, sponsored by the American Society for Microbiology.

Glycerol treatment led to better outcomes for all parameters analyzed. When death and severe neurologic sequelae were combined as an end point, patients with Glasgow Coma Scale scores of less than


13 who were treated with glycerol had 55% fewer events than those treated with placebo.

"The mechanisms of glycerol's effect are not fully understood, but improved cerebral circulation seems a likely explanation," Dr. Peltola said. It's also unclear why the combination of glycerol and dexamethasone was less effective than glycerol alone.

"I'm pleased to see these results. It's a superb idea because of the low cost and ready availability of glycerol," commented Neal A. Halsey, M.D., director of the Institute for Vaccine Safety at Johns Hopkins University in Baltimore. ■

Attenuated live vaccines are safe and effective

Questions about influenza vaccine efficacy often arise during years with *strain mismatch*—years in which the predicted strains do not match the prevailing wild influenza virus. The efficacy of FluMist®, the only commercially available CAIV, has been demonstrated even in a year with mismatched strains. In a subgroup from a 2-year clinical study in children aged 5 and older, FluMist® reduced the number of children contracting influenza by 87% vs placebo during both the year with mismatched strains (1997-1998) and the year with matched strains (1996-1997).¹



* Results from a multicenter, randomized, double-blind, placebo-controlled trial in 544 healthy children 60-84 months of age. Percentage of vaccinated children (n=375) who developed influenza vs those receiving placebo (n=169) was 1.9% vs 14.2%.

¹ Results from a multicenter, randomized, double-blind placebo-controlled trial in 238 healthy children 60-71 months of age who received 2 doses of FluMist® (n=163) or placebo (n=75). Percentage of vaccinated children who developed influenza vs those receiving placebo was 1.8% vs 14.7%.

A first line of defense

The cold-adapted vaccine strains replicate primarily in the nasopharynx, initiating an immune response at influenza's point of entry. Due to temperature sensitivity, the vaccine strains in FluMist® do not replicate efficiently in the warmer temperatures of the lower airways and lungs.¹

Substantial efficacy, combined with a demonstrated safety profile, makes FluMist® an effective choice to help protect your healthy patients this influenza season and in the seasons to come.

FluMist® is indicated for active immunization for the prevention of disease caused by influenza A and B viruses in healthy children and adolescents, 5 to 17 years of age, and healthy adults, 18 to 49 years of age. There are risks associated with all vaccines, including FluMist®. FluMist® does not protect 100% of individuals vaccinated, and may not protect against viral strains not represented in the vaccine.

In placebo-controlled clinical trials, the most common solicited adverse events in the indicated population (n=2,762) included runny nose/nasal congestion, headache, cough, sore throat, tiredness/weakness, irritability, decreased activity, and muscle aches.

FluMist® is contraindicated in persons with hypersensitivity to any component of the vaccine, including eggs; in children and adolescents receiving aspirin therapy or aspirin-containing therapy; in individuals with a history of Guillain-Barré syndrome; and in individuals with known or suspected immune deficiency. The safety and efficacy of FluMist® have not been established in pregnant women or for patients with chronic underlying medical conditions, including asthma or reactive airways disease; the vaccine should not be administered to these patients.

For indications and usage, dosage and administration, and safety information, see the Brief Summary on the adjacent page. For more information, visit flumist.com.

REFERENCE 1. Prescribing Information for FluMist®, Influenza Virus Vaccine Live, Intranasal. MedImmune Vaccines, Inc., Gaithersburg, MD.

Manufactured and Marketed by:

MedImmune Vaccines, Inc.
Gaithersburg, MD 20878
U.S. Govt. License No. 1652

©2005 MedImmune Vaccines, Inc.

January 2005

FLU04-249

fluMist
Influenza Virus Vaccine
Live, Intranasal